Bosentan
Bosentan is a pharmaceutical drug with 80 clinical trials. Currently 3 active trials ongoing. Historical success rate of 79.4%.
Success Metrics
Based on 50 completed trials
Phase Distribution
Phase Distribution
15
Early Stage
22
Mid Stage
35
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
78.1%
50 of 64 finished
21.9%
14 ended early
3
trials recruiting
80
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Pulmonary Artery Remodelling With Bosentan
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Bosentan in Systemic Sclerosis
Clinical Trials (80)
A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Pulmonary Artery Remodelling With Bosentan
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)
Bosentan in Systemic Sclerosis
Bosentan in the Treatment of Giant Cell Arteritis
Effect of Bosentan in Scleroderma Renal Crisis
A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood
Endothelin-1 Receptor Blockade in Resistant Hypertension
Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea
A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
FUTURE 3 Study Extension
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
Persistent Pulmonary Hypertension of the Newborn
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients Diagnosed With Pulmonary Hypertension (PH)
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 80